Hester Biosciences says on track to produce Covaxin drug substance by Q4FY22

Hester Biosciences says on track to produce Covaxin drug substance by Q4FY22 The construction of a BSL-3 facility suitable for manufacturing the drug substance of Covaxin is underway. The vaccine maker intends to produce 5 million to 15 million doses of Covaxin drug substance.

No comments:

Post a Comment